Thiogenesis Therapeutics, Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of a range of unmet genetic and central nervous system diseases. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine and pantetheine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke. The company is headquartered in Toronto, Canada.
Research context
Rozdil Capital Corporation appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Financial Services
- Industry
- Shell Companies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Rozdil Capital Corporation is currently in a long term downtrend where the price is trading 0.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 0.0.
Rozdil Capital Corporation's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 110.0% to $-17K since the same quarter in the previous year.
Finally, its free cash flow fell by 18.3% to $-6K since the same quarter in the previous year.
Based on the above factors, Rozdil Capital Corporation gets an overall score of 1/5.